Fresenius Medical Care Showcases Innovative Kidney Research at ERA Congress 2026

Fresenius Medical Care (FME), a global leader in kidney care, is set to present significant advancements in renal research during the upcoming European Renal Association (ERA) Congress 2026, scheduled for June 3-6 in Glasgow, Scotland. The Congress will also be accessible virtually, enabling a wider audience to engage with the latest breakthroughs in kidney disease treatment.

As the foremost provider of products and services for individuals suffering from kidney diseases, Fresenius Medical Care is dedicated to continuous innovation. A key focus of this year’s presentations will be on the latest findings from hemodiafiltration (HDF) research, emphasizing the company's commitment to evidence-based and personalized dialysis care. Charles Hugh-Jones, the Global Chief Medical Officer at FME, emphasized, "Our research aims to significantly enhance the quality of care for individuals living with chronic kidney disease."

Key Areas of Research Presented

At the ERA Congress, FME will unveil new studies covering various pertinently impactful topics in nephrology:
1. Impact of Matching Strategies on Patient Outcomes - A real-world analysis indicates that hemodiafiltration may lower three-year mortality risks compared to traditional hemodialysis.
2. Recovery Time and Treatment Adherence - Research highlights that patients experiencing prolonged recovery times after treatments often report higher rates of missed sessions, pointing to the need for improved patient support.
3. Artificial Intelligence in Peritoneal Dialysis - The use of AI-driven models that identify patients likely to discontinue peritoneal dialysis correlates with reduced hospitalization rates, showcasing how technology can enhance care management.
4. AI in Systematic Reviews - A high-precision language model like GPT-5 can streamline the research process by identifying the most relevant studies for review, promising to accelerate advancements in the field.

Fresenius Medical Care's Global Medical Office and Renal Research Institute teams will jointly present various abstracts underscoring how artificial intelligence can unlock new insights and foster patient-centered care decision-making.

Innovations at the Forefront

Among the many unveilings at the Congress, FME will preview "kinexus," a unified digital platform aimed at transforming home dialysis programs by integrating therapy management and operational workflows into a singular, user-friendly ecosystem. This initiative illustrates FME's ongoing commitment to simplifying processes for healthcare teams while providing high-quality, individualized care for patients managing their treatment from home.

Delegates attending the event can meet FME leaders and researchers at Booth #C.210 and the Renal Research Institute's Booth #C.410, where discussions will emphasize the latest research insights, clinical collaborations, and innovative strategies to advance kidney care.

Conclusion

With around 4.5 million patients globally undergoing dialysis, Fresenius Medical Care's role as a leader in kidney treatment innovation becomes increasingly vital. The insights shared at the ERA Congress promise to guide practitioners in making better-informed clinical choices and bolstering patient outcomes across nephrology settings. This year's Congress signifies not just an academic gathering but a pivotal moment for the future of renal healthcare, with Fresenius Medical Care at the forefront.

To learn more about FME's involvement and initiatives at ERA Congress 2026, visit their official website.